156 related articles for article (PubMed ID: 33855929)
1. Application of deep learning and molecular modeling to identify small drug-like compounds as potential HIV-1 entry inhibitors.
Andrianov AM; Nikolaev GI; Shuldov NA; Bosko IP; Anischenko AI; Tuzikov AV
J Biomol Struct Dyn; 2022 Oct; 40(16):7555-7573. PubMed ID: 33855929
[TBL] [Abstract][Full Text] [Related]
2. In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4.
Andrianov AM; Nikolaev GI; Kornoushenko YV; Xu W; Jiang S; Tuzikov AV
Viruses; 2019 Aug; 11(8):. PubMed ID: 31412617
[TBL] [Abstract][Full Text] [Related]
3. Computational discovery of novel HIV-1 entry inhibitors based on potent and broad neutralizing antibody VRC01.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Graph Model; 2015 Sep; 61():262-71. PubMed ID: 26298811
[TBL] [Abstract][Full Text] [Related]
4. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
5. In silico design of novel broad anti-HIV-1 agents based on glycosphingolipid β-galactosylceramide, a high-affinity receptor for the envelope gp120 V3 loop.
Andrianov AM; Kornoushenko YV; Kashyn IA; Kisel MA; Tuzikov AV
J Biomol Struct Dyn; 2015; 33(5):1051-66. PubMed ID: 24942968
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.
Courter JR; Madani N; Sodroski J; Schön A; Freire E; Kwong PD; Hendrickson WA; Chaiken IM; LaLonde JM; Smith AB
Acc Chem Res; 2014 Apr; 47(4):1228-37. PubMed ID: 24502450
[TBL] [Abstract][Full Text] [Related]
7. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
8. Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Model; 2017 Jan; 23(1):18. PubMed ID: 28050723
[TBL] [Abstract][Full Text] [Related]
9. Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120.
Vangala R; Sivan SK; Peddi SR; Manga V
J Comput Aided Mol Des; 2020 Jan; 34(1):39-54. PubMed ID: 31792886
[TBL] [Abstract][Full Text] [Related]
10. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.
Schön A; Madani N; Klein JC; Hubicki A; Ng D; Yang X; Smith AB; Sodroski J; Freire E
Biochemistry; 2006 Sep; 45(36):10973-80. PubMed ID: 16953583
[TBL] [Abstract][Full Text] [Related]
11. Does Antibody Stabilize the Ligand Binding in GP120 of HIV-1 Envelope Protein? Evidence from MD Simulation.
Yadav S; Pandey V; Kumar Tiwari R; Ojha RP; Dubey KD
Molecules; 2021 Jan; 26(1):. PubMed ID: 33466381
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study.
Andrianov AM; Kashyn IA; Tuzikov AV
J Biomol Struct Dyn; 2014 Dec; 32(12):1993-2004. PubMed ID: 24251545
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling.
Berinyuy E; Soliman MES
Interdiscip Sci; 2017 Sep; 9(3):406-418. PubMed ID: 27165479
[TBL] [Abstract][Full Text] [Related]
14. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120.
Tintori C; Selvaraj M; Badia R; Clotet B; Esté JA; Botta M
ChemMedChem; 2013 Mar; 8(3):475-83. PubMed ID: 23404750
[TBL] [Abstract][Full Text] [Related]
15. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
16. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors.
Tiberi M; Tintori C; Ceresola ER; Fazi R; Zamperini C; Calandro P; Franchi L; Selvaraj M; Botta L; Sampaolo M; Saita D; Ferrarese R; Clementi M; Canducci F; Botta M
Antimicrob Agents Chemother; 2014 Jun; 58(6):3043-52. PubMed ID: 24614386
[TBL] [Abstract][Full Text] [Related]
17. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].
Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191
[TBL] [Abstract][Full Text] [Related]
18. E-pharmacophore based screening to identify potential HIV-1 gp120 and CD4 interaction blockers for wild and mutant types.
Chandra I; Prabhu SV; Nayak C; Singh SK
SAR QSAR Environ Res; 2021 May; 32(5):353-377. PubMed ID: 33832362
[TBL] [Abstract][Full Text] [Related]
19. A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.
Emileh A; Tuzer F; Yeh H; Umashankara M; Moreira DR; Lalonde JM; Bewley CA; Abrams CF; Chaiken IM
Biochemistry; 2013 Apr; 52(13):2245-61. PubMed ID: 23470147
[TBL] [Abstract][Full Text] [Related]
20. In silico study on indole derivatives as anti HIV-1 agents: a combined docking, molecular dynamics and 3D-QSAR study.
Balupuri A; Gadhe CG; Balasubramanian PK; Kothandan G; Cho SJ
Arch Pharm Res; 2014 Aug; 37(8):1001-15. PubMed ID: 24338530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
